Voyager Therapeutics (VYGR) presented its strategic focus on Alzheimer’s disease treatments at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, emphasizing its tau-targeting programs and partnerships. The company reported a 19% year-over-year decline in revenue to $34.5 million over the past twelve months, yet eight analysts revised their earnings estimates upward, with price targets ranging from $8 to $25 per share. The biotech firm’s efforts center on two key initiatives: a tau antibody (VY-7523) and a gene therapy (VY1706) designed to silence tau protein accumulation in the brain, a hallmark of Alzheimer’s pathology.
The tau antibody program, targeting the C-terminal of tau via a multiple ascending dose study, is benchmarked against bepranemab, which demonstrated about 40% to 50% slowing of tau spread in PET imaging. Voyager’s candidate must match or exceed this performance to proceed. Early data from a transgenic mouse model suggests the antibody achieves a brain-to-plasma ratio of roughly 0.3%, with potential improvements via its NeuroShuttle platform.
A second priority is VY1706, a gene therapy using a next-generation blood-brain barrier penetrant capsid to deliver siRNA for tau silencing. The program has secured regulatory clearance from the FDA and Health Canada, with site activation underway and first patient enrollment expected in 2024. Acute safety data is due in Q1 2025, followed by cerebrospinal fluid tau-lowering results in the second half of 2025. Non-human primate studies indicate a 60% to 70% tau knockdown at maximum doses of 5E13 vg/kg, with a 30-fold reduction in liver exposure compared to AAV9.
Voyager’s NeuroShuttle platform leverages novel receptors, such as ALPL, to enhance delivery across the blood-brain barrier without hematologic side effects. CEO Al Sandrock highlighted the company’s collaboration with industry leaders like Neurocrine Biosciences (five partner programs) and Novartis (three programs), as well as an existing alliance with Alexion (formerly Pfizer).
The discussion underscored the competitive landscape, with Biogen’s BIIB080 showing unprecedented cognitive efficacy in ADAS-Cog measures but also raising concerns about acute confusional states tied to intrathecal delivery. Sandrock emphasized ethical considerations, stressing that even low-dose therapies must demonstrate meaningful patient benefit.
Voyager’s focus on Alzheimer’s reflects broader industry momentum toward tau-targeting therapies, with 2024 marked as a pivotal year for such approaches, according to Sandrock. The company’s pipeline positions it as a key player in advancing treatments for a disease that remains a major unmet medical need.
